Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
it'll keep going lower until it has a reason to go higher.
or no position. Getting old.
the more i see of Anavex the more I think: it's a cult stock without a leader.
I keep on forgetting. New times!
if he needs AD treatment, most of the board needs shock treatment.
agreed, good one. Hoping it all comes true (but I'll take a half of it, even a quarter).
good for your father. Mine father as well.
Death is a funny business: the mind doesn't know where to go when it has to deal with it.
It makes me think: get the damned thing to the people, fast.
Another article. Someone posts these articles on another board.
http://beta.latimes.com/opinion/op-ed/la-oe-welsh-cancer-immunotherapy-20160717-snap-story.html
A bit dated (Feb. 2017). PBS doc. Dr. Alain Algazi in it, along with treated cancer patient.
https://www.pbs.org/newshour/show/cancer-immunotherapy-life-saving-powers-limits
script numbers look good, considering 4-day week. On we go!
basically, it's restrictions on the re-sell. No new shares were issued. No new dilution.
Now we're down to one trial! What happened to the three trials that were supposed to start in 2017? LOL.
F1ash, keep digging, keep up the good work. I don't agree with the post about life and statistics aren't everything and science has surprises stuff. We're talking about a clinical trial, where method matters. So far Anavex science does not defend itself with facts. Hence, the share price. Once a Ph2b confirmatory trial is run, we'll know the truth. Until then, statistically, you are right.
Why does this Ph2a data continue to be ambiguous? It's as if, well, they didn't want to show everything.
Big Pharma.
It's about incompetence.
I'll add if it drops tomorrow.
thanks. very informative
Look, if Bill Gates thought Anavex had the goods, he would have board the company. Pocket change. He's like the Street: no one believes in the data, while Missling twiddles his thumbs. Why? What's he waiting for? He's been waiting a long time. And where is the share price?
it's called moving the goal posts.
staccini,
Can you tell from the data if any Stage IV patients responded? I believe there were 9 Stage IV patients.
Btw, I have been in IDRA for over three years. Promising data as well.
My bet: shorts start playing with it again, knowing the catalyst dates, expecting another raise. I hope it to drops to 2. Will load up and then sell at 2.50. Rinse and repeat. It will gain momentum as we trudge through 1H 2018, screaming to a climax around July.
Holding onto my long position.
But there’s the difference. Those who have done deep diligence and understood the unique science of the Anavex sigma-1 receptor agonists know full well the near-certain outcomes of the upcoming clinical trials.
Really? Near-certain outcomes? LOL!
I can't wait to see what happens after data? BTD might even happen before then.
How long I will it take to enroll 48 participants? Started October 3. Three or four sites, I believe. Then six months from there. After that, if data is great, FDA will not wait for extention to be completed, imo.
That's good, isn't it? They don't lose track of patients, and they can take a peek every once in a while to see what's in it. Ideal!
Well, then, all the better, isn't it, doc?
apparently, judging from recent SITC data, they're not bad at running clinical trials either. I know most retail hate the guy, but when Adam Feuerstein has joined the bandwagon, that's when it starts to get interesting; at least you can say the drug is legitimate. The guy has the best nano-cap biotech bullshit detector I have ever seen. Not always right, of course, but he cuts through a lot of bs. In the case of ONCS, at least he has given it the benefit of the doubt, and that's saying something, coming from him.
Hope so. Not holding my breath. I haven't moved on, but I've definitely lightened my load. Honestly, I'm growing impatient with the ambiguity and delays. Let's just get a trial started and see what kind of efficacy we have at the finish line. Period.
the longer the wait, the shorter it gets.
Both serious and sarcastic.
Mike, respond to my question. In the case of Alzheimer's, I believe there have been about 200-300 clinical trials--don't remember, exactly. Would you rather have been short or long?
just saying: aint too hard to understand the rationale behind shorting AVXL. Odds are against successful trial.
That's the think longs don't consider, investor. How many effective drugs are there on the market to treat Rett's? If you were a betting man, which side would you take? Same goes for AD. I'm not short; I've never shorted a stock; but I understand the long game here. They could lose tomorrow, and lose big, but in the long run they'll probably end up winning. Just take all of the AD drug trials over the years and ask yourself: who came out ahead? Sure, it's much more complicated than that. When you bought. When you sold. But, in the end of all these trials, I'd rather get the short end of the stock, if you get my drift.
Titan, when's the next ONCS catalyst? Thanks.
it will go up--or down, eventually--based on the Street's belief in the drug. In reality, what will probably happen is this: the MMs will bid it up for a month or two, then short the hell out of it before Data Day.